Stem cell shot aims to mend brittle bones in older women
NCT ID NCT06949137
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing a new stem cell treatment called HMM910 in 9 postmenopausal women with osteoporosis who are at high risk of breaking a bone. The stem cells are given through an IV drip. The main goal is to see if the treatment is safe and tolerable, not yet to prove it works. If it passes safety checks, larger studies could explore whether it actually strengthens bones.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
human umbilical cord-derived mesenchymal stem cells (HMM910)
What this could lead to
If safe and effective, this could point toward a new treatment to strengthen bones and reduce fracture risk in postmenopausal women with osteoporosis.
What could go wrong
This is a very early Phase 1 trial with only 9 participants, so it is primarily testing safety, not effectiveness. The stem cell approach may not improve bone health and could cause unexpected side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOPOROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
HELP Therapeutics
Nanjing, Jiangsu, 210000, China